Children's Oncology Group Trial AALL1231: A Phase III Clinical Trial Testing Bortezomib in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia and Lymphoma

T. Teachey, David; Devidas, Meenakshi; L. Wood, Brent; Chen, Zhiguo; J. Hayashi, Robert; L. Hermiston, Michelle; D. Annett, Robert; Archer, Jan-Michael; L. Asselin, Barbara; J. August, Keith; Y. Cho, Steve; P. Dunsmore, Kimberly; T. Fisher, Brian; L. Freedman, Jason; J. Galardy, Paul; Harker‐Murray, Paul; M. Horton, Terzah; Jaju, Alok; Lam, Allison; H. Messinger, Yoav; R. Miles, Rodney; Okada, Maki; Patel, Samir; S. Schafer, Eric; Schechter, Tal; Singh, Neelam; C. Steele, Amii; Luisa Sulis, Maria; Vargas, Sarah; S. Winter, Stuart; Wood, Charlotte; A. Zweidler‐McKay, Patrick; M. Bollard, Catherine; L. Loh, Mignon; P. Hunger, Stephen; A. Raetz, Elizabeth

doi:10.1200/jco.21.02678

Public

Children's Oncology Group Trial AALL1231: A Phase III Clinical Trial Testing Bortezomib in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia and Lymphoma

Published in Journal of Clinical Oncology • Mar 10, 2022

Authors:

David T. Teachey

Meenakshi Devidas

Brent L. Wood

Abstract

PURPOSE To improve the outcomes of patients with T-cell acute lymphoblastic leukemia (T-ALL) and lymphoblastic lymphoma (T-LL), the proteasome inhibitor bortezomib was examined in the Children's Oncology Group phase III clinical trial AALL1231, which also attempted to reduce the use of prophylactic ...

Subject

Medicine

Bortezomib

Internal medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!